2026 Clinical Update. Public health guidance for the conditions Sickday’s licensed clinicians most commonly evaluate has continued to evolve through 2026, with updated treatment protocols, refreshed risk-factor framing, and current epidemiological context for the New York metro region. For patients evaluating symptoms and considering when a remote or in-home clinical visit is appropriate, the most current authoritative sources include the CDC, NYC Department of Health, and NIH-published clinical guidance. The remainder of this article — originally published in an earlier cycle and updated here for 2026 — covers the underlying clinical and practical detail in the context of those current sources. As with any health matter, the information here is educational and does not replace direct evaluation by a licensed clinician.
The strongest candidates so far are considered to be rom the University of Oxford with AstraZeneca Plc, Moderna Inc. and a partnership of Pfizer Inc. and BioNTech SE. In reality, these are simply the COVID-19 vaccine candidates closer to approval and currently on phase 3. A phase 3 clinical trial still involve high risk that the vaccine may actually not be proven effective. In short, Phase 3 trials do fail.
Aside the prevention efforts targeting the coronavirus vaccine development, there is a large focus on treatments for active COVID-19 infections. Antivirals, are drugs that work by stopping the virus from replicating inside our cells or infecting new cells. The most promising coronavirus treatment candidate so far is Remdesivir by Gilead Sciences Inc.
Several other approaches are in place such as anti-COVID-19 antibodies currently in phase 3 and a phase 2 antiviral by Merck & Co. code named MK-4482.
As the world is working together for prevention and treatment, everyone hopes that soon we will claim a victory against the pandemic.
